ATH 25.0% 0.5¢ alterity therapeutics limited

Hi mate. I Saw it on CommSec. ACW announcement this morning....

  1. 1,155 Posts.
    lightbulb Created with Sketch. 104
    Hi mate.

    I Saw it on CommSec. ACW announcement this morning.

    Copied part of it for you below. I'm not sure what this means for us!!


    POWERHOUSE ALZHEIMER'S ADVISORY BOARD TO DRIVE XANAMEMTM DEVELOPMENT

    • World leading experts in early Alzheimer’s and Mild Cognitive Impairment (MCI) diagnosis and treatment join XanamemTM Advisory Board

    • XanamemTM’s novel mechanism of action setting it apart from other Alzheimer’s treatments through blocking the production of cortisol, has attracted a powerhouse Advisory Board.

    • Advisory Board to help design the optimum Phase II efficacy trial for XanamemTM in Alzheimer’s and MCI patients

    • Phase II study to start in early 2016 and expected to be run in the USA (under a Food and Drug Administration (FDA) approved Investigational New Drug (IND)), ANZ and the EU

      Sydney, 17 March 2015: Actinogen Limited (Actinogen Medical, ASX: ACW), is delighted to announce the appointment of a powerhouse team of globally recognised leaders in Alzheimer’s disease research to its XanamemTM Advisory Board - Professor Craig Ritchie from Edinburgh UK, Professor Colin Masters from Melbourne Australia and Professor Jeff Cummings from the Cleveland Clinic USA. This Advisory Board has particular expertise in the early diagnosis and treatment of Alzheimer’s disease and will help Actinogen Medical shape and drive the development of its new lead research drug, XanamemTM.

      XanamemTM is a new promising treatment for early Alzheimer’s disease and its precursor stage, Mild Cognitive Impairment. XanamemTM’s novel mechanism of action sets it apart from existing Alzheimer’s treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease. Thomson Reuters recently rated XanamemTM in the top five drugs in Phase I development globally.

      The first major priority for the Advisory Board will be to assist Actinogen Medical in designing the optimum Phase II study to best demonstrate the efficacy and safety of XanamemTM in patients with Mild Cognitive Impairment and Alzheimer’s disease. Actinogen Medical expects to start this study in early 2016 and for it to run in Australia/New Zealand, Europe and the USA, under an FDA approved IND. The broad geographic spread of the members of the XanamemTM Advisory Board will provide a true global dimension to Actinogen Medical’s research strategy for XanamemTM.

      The Advisory Board will be chaired by Professor Craig Ritchie, Professor of Psychiatry of Ageing at the University of Edinburgh. Professor Ritchie is a leading authority on clinical trials in dementia and has been senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. He has extensive knowledge of the industry, having sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer’s disease. Professor Ritchie is also leading the PREVENT project, a major Scottish initiative to identify mid-life risks for dementia and the EPAD (European Prevention of Alzheimer’s Dementia) consortium to better understand early aspects of Alzheimer’s disease before dementia develops. He has published extensively on the topics of dementia and delirium.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.